Q-omics provides the consensus-scored RPS20P22 profile across patient tissues and cancer cell-line models. RPS20P22 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPS20P22 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPS20P22 RNA expression shows 17,085 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where RPS20P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P22 survival associations across molecular data types. RPS20P22 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P22 RNA expression–survival associations across cancer types. High RPS20P22 expression shows unfavorable associations in UVM, STAD, BLCA, LGG, KIRC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPS20P22 RNA expression.
This table summarizes RPS20P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P22 shows lower tumor expression in COAD, BLCA, KIRC, LUAD and THCA and higher tumor expression in UCEC. The COAD box plot shows higher RPS20P22 RNA expression in normal versus tumor tissue (log2 FC = −0.176, t-test p < 0.001).
This table shows molecular features associated with RPS20P22 in patient tissues and cancer cell lines. In patient samples, RPS20P22 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
